References
-
1) Cornuside protects against ischemic stroke in rats by suppressing the IL-17F/TRAF6/NF-κB pathway via the brain-gut axis.
Product: IL17RA Antibody (#DF3602)Year: 2024Journal: Exp NeurolImpactFactor: 4.6DOI: 10.1016/j.expneurol.2023.114672PMID: 38169196 -
2) Gingerenone A Attenuates Ulcerative Colitis via Targeting IL-17RA to Inhibit Inflammation and Restore Intestinal Barrier Function.
Product: IL17RA Antibody (#DF3602)Year: 2024Journal: Adv Sci (Weinh)ImpactFactor: 15.1DOI: 10.1002/advs.202400206PMID: 38639442 -
3) Development and Validation of a 7-Gene Inflammatory Signature Forecasts Prognosis and Diverse Immune Landscape in Lung Adenocarcinoma.
Product: IL17RA Antibody (#DF3602)Year: 2022Journal: FRONT MOL BIOSCIImpactFactor: 5DOI: 10.3389/fmolb.2022.822739PMID: 35372503 -
4) IL-17A exacerbates cisplatin-based resistance of OVCA via upregulating the expression of ABCG2 and MDR1 through Gli1-mediated Hh signaling.
-
5) FGF23 alleviates neuronal apoptosis and inflammation, and promotes locomotion recovery via activation of PI3K/AKT signalling in spinal cord injury.
Product: FGF23 Antibody (#DF3596)Year: 2023Journal: Exp Ther MedImpactFactor: 2.4DOI: 10.3892/etm.2023.12039PMID: 37383378 -
6) IL-6, IL-1β and TNF-α regulation of the chondrocyte phenotype: a possible mechanism of haemophilic cartilage destruction.
Product: FGF23 Antibody (#DF3596)Year: 2023Journal: HematologyImpactFactor: 2DOI: 10.1080/16078454.2023.2179867PMID: 36799502 -
7) Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles.
Product: FGF23 Antibody (#DF3596)Year: 2022Journal: Bioact MaterImpactFactor: 18.9DOI: 10.1016/j.bioactmat.2022.01.007PMID: 35386445 -
8) FGF-18 Protects the Injured Spinal cord in mice by Suppressing Pyroptosis and Promoting Autophagy via the AKT-mTOR-TRPML1 axis.
Product: FGF18 Antibody (#DF3595)Year: 2023Journal: Mol NeurobiolImpactFactor: 4.6DOI: 10.1007/s12035-023-03503-8PMID: 37581847 -
9) Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1.
Year: 2021Journal: BREAST CANCER RES TRImpactFactor: 3DOI: 10.1007/s10549-021-06435-wPMID: 34725776 -
10) Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Year: 2021Journal: INT IMMUNOPHARMACOLImpactFactor: 4.8DOI: 10.1016/j.intimp.2021.108087PMID: 34464888 -
11) Involvement of WNT2 in trophoblast cell behavior in preeclampsia development.
-
12) Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.
Year: 2019Journal: INT IMMUNOPHARMACOLImpactFactor: 4.8DOI: 10.1016/j.intimp.2019.05.003PMID: 31082724 -
13) An Engineered Protein-Based Building Block (Albumin Methacryloyl) for Fabrication of a 3D In Vitro Cryogel Model.
-
14) Effects of total saikosaponins on CYP3A4 and CYP1A2 in HepaRG cells.
-
15) Advanced oxidation protein products downregulate CYP1A2 and CYP3A4 expression and activity via the NF-κB-mediated signaling pathway in vitro and in vivo.